Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age

Keyphrases

• Clinical Significance 100%
• Gestational Age 100%
• Respiratory Syncytial Virus 100%
• Lower Respiratory Tract Infection 100%
• Preterm Infants 100%
• Risk Factors 20%
• Hospitalization 20%
• High Risk 10%
• Increased Vulnerability 10%
• Age Groups 10%
• Predictive Models 10%
• Environmental Risk Factors 10%
• Premature Infant 10%
• Lung Development 10%
• Social Risk 10%
• Palivizumab 10%
• Respiratory Syncytial Virus Hospitalization 10%
• Effective Method 10%
• Public Health Needs 10%
• Acknowledgment 10%
• Potential Consequences 10%
• Immature Immune System 10%
• Underlying Risk Factors 10%
• High-risk Infants 10%
• Respiratory Morbidity 10%
• Perspectives of Others 10%
• Healthcare Resources 10%
• Physiological Risk Factors 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Human Respiratory Syncytial Virus 100%
• Lower Respiratory Tract Infection 100%
• Prematurity 9%
• Palivizumab 9%

Nursing and Health Professions

• Nutrition Policy 10%